Protocolo terapéutico de la insuficiencia cardíaca crónica

  1. Amores Luque, M.C. 1
  2. Sánchez Vega, J.D. 1
  3. Alonso Salinas, G.L. 1
  4. Zamorano Gómez, J.L. 1
  1. 1 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades cardiovasculares (I)

Serie: 13

Número: 35

Páginas: 2054-2057

Tipo: Artículo

DOI: 10.1016/J.MED.2021.06.007 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Chronic heart failure (CHF) is a major problem in our setting, affecting 1%-2% of the adult population in developed countries, and whose prevalence exceeds 10% in those over the age of 70. Treatment of CHF aims to improve functional class, quality of life, prevent hospitalisation and reduce mortality. It is important to distinguish patients with CHF and reduced left ventricular ejection fraction (HF with rLVEF less than 40%) from those with mid-range (HF with mLVEF, 40%-50%) or preserved left ventricular ejection fraction (pLVEF, greater than 50%), as there are significant implications for pharmacological treatment. Management of these patients is complex, especially those with reduced LVEF, and often requires a multidisciplinary approach in CHF units that combine different specialties such as cardiology, internal medicine, nephrology, cardiac surgery, rehabilitation, geriatrics, and palliative care.

Referencias bibliográficas

  • Seferovic, P.M., Ponikowski, P., Anker, S.D., Bauersachs, J., Chioncel, O., Cleland, J.G.F. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail., 21 (10) (2019), pp. 1169-1186
  • Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Colvin, M.M. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol., 70 (6) (2017), pp. 776-803
  • McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Køber, L., Kosiborod, M.N., Martínez, F.A. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med., 381 (21) (2019), pp. 1995-2008
  • Armstrong, P.W., Pieske, B., Anstrom, K.J., Ezekowitz, J., Hernández, A.F., Butler, J. Vericiguat in patients with heart failure and reduced ejection fraction. New Engl J Med., 382 (20) (2020), pp. 1883-1893
  • Teerlink, J.R., Díaz, R., Felker, G.M., McMurray, J.J.V., Metra, M., Solomon, S.D. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of galactichf. JACC Heart Fail., 8 (4) (2020), pp. 329-340
Fuente de los datos: Dialnet